Trudhesa (formally, INP 104) was first approved for acute treatment of migraine on September 2, 2021. Trudhesa uses nasal delivery of DHE (Dihydroergotamine mesylate), 0.725mg per spray. Dihydroergotamine mesylate is a well-established migraine treatment with more than 70 years of therapeutic use. Trudhesa, is advanced because it bypasses the gastrointestinal absorption to provides a quicker delivery of DHE into the bloodstream through vascular -rich upper nasal space. Trudhesa is not indicated for the preventive treatment of migraine or for the management of hemiplegic or basilar migraine. This approval provides another abortive option for a patient to add to their migraine toolbox. Please call The Manhattan Center for Headache & Neurology to speak with one of our caring providers about questions regarding this new advancement in acute migraine treatment!

Jordan Shankle, PA